Progenics and Ono to Codevelop Relistor in Japan

Ono have signed an agreement to license Relistor (methylnaltrexone bromide) from Progenics for development in Japan

Orexigens naltrexone SR shows efficacy in Phase I

Data presented at the Obesity Society Annual Scientific Meeting show Orexigen Therapeutic’s sustained release formulation of naltrexone, Contrave, achieved key objectives (lowered naltrexone Cmax, increased Tmax, comparable AUC) in two Phase 1 clinical trials.

ProStrakan extend deal with Orexo for Rapinyl

ProStrakan have extended its existing European licensing agreement for Rapinyl with its Swedish partner Orexo to include North America.

Titan announces positive Phase III results for probuphine in Opioid addiction

Titan Pharmaceuticals have announced positive, statistically significant results from its phase III clinical trial of Probuphine in the treatment of opioid addiction.

Akela Pharma to repeat Fentanyl TAIDUN tests at request of FDA

Akela Pharma have announced that it will repeat required inhalation toxicology studies at the request of the FDA before commencing long term safety Phase III trials

FDA lift clinical hold on Adolors Entereg (alvimopan) program for chronic opioid bowel dysfunction (OBD).

FDA lift clinical hold on Adolors Entereg (alvimopan) program for chronic opioid bowel dysfunction (OBD).

ProStrakan receives positive EMEA opinion for Rapinyl (Abstral) in cancer pain

The EMEA has issued a positive opinion for ProStrakan’s sublingual fentanyl product Rapinyl (Abstral) for use in cancer pain.

FDA lifts clinical hold on Aerolef

YM BioSciences have announced that the FDA has lifted a clinical hold posed on its inhaled fentanyl compounf AeroLEF.

Phase III enrollment for Contrave Complete

Orexigen have announced that Enrollment in a Phase III Clinical Trials for Contrave (naltrexone + bupropion) is complete. An NDA filing is expected in late 2009.

Controlled release Vicodin meets Phase III endpoints

Abbotts’s Vicodin CR (hydrocodone bitartrate and acetaminophen) has met efficacy endpoints in a Phase III trial in patients with chronic low back pain